The 2018 Society of Urologic Oncology (SUO) Meeting was second to none – an outstanding array of speakers and sessions that addressed virtually every salient point pertaining to renal cell carcinoma (RCC) treatment.  As you can imagine, cytoreductive nephrectomy was a hot topic for discussion – SUO 2018 marked the first large US
I’m back now from a short stay in Munich for ESMO 2018 – didn’t get much beer or bratwurst, but I did soak in as much of the meeting as I could. The conference spanned a full five days – a little too much for my clinical schedule to handle – but I did get my hands on the bulk of the important renal cell carcinoma (RCC) data from the meeting.  I’ve boiled it down to three brief bullet points:
When I finished training and joined the faculty at City of Hope a decade ago, there was a great deal of excitement over recent approvals of sunitinib and sorafenib for metastatic renal cell carcinoma (mRCC).  Throughout my training, I had seen many patients succumb to toxicities from interleukin-2 – despite the handful of victories, there were overwhelming losses. 
Welcome to the Advanced Kidney Cancer Center of Excellence on  My name is Monty Pal, and I am a medical oncologist with just over a decade of experience in a research-based practice primarily focused on RCC and other genitourinary cancers.  I recall that when I began, our treatment options were limited. 


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.